Oppenheimer Reiterates Outperform Rating on Crinetics (CRNX)

January 6, 2026 6:58 AM UTC Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $87.00 price target on Crinetics (NASDAQ: CRNX).The analyst commented: "CRNX reported ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login